Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus DYCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus DYCILL.
CLOXAPEN vs DYCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic